Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study

Samah Hayek; Yatir Ben-Shlomo; Ran Balicer; Katherine Byrne; Mark Katz; Eldad Kepten; Itamar Raz; Eytan Roitman; Marcin Zychma; Noam Barda

doi:10.1111/dom.14393

Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study

Samah Hayek^*
, Yatir Ben-Shlomo
, Ran Balicer
, Katherine Byrne
, Mark Katz
, Eldad Kepten
, Itamar Raz
, Eytan Roitman
, Marcin Zychma
, Noam Barda

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	1995-2000
Number of pages	6
Journal	Diabetes, Obesity and Metabolism
Volume	23
Issue number	8
DOIs	https://doi.org/10.1111/dom.14393
State	Published - Aug 2021
Externally published	Yes

Funding

Funders
Clalit Research Institute
Novo Nordisk

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dom.14393

Cite this

@article{63221656dcea4274914ca8396f961b0e,

title = "Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study",

author = "Samah Hayek and Yatir Ben-Shlomo and Ran Balicer and Katherine Byrne and Mark Katz and Eldad Kepten and Itamar Raz and Eytan Roitman and Marcin Zychma and Noam Barda",

note = "Funding Information: SH, YB‐S, RB, MK, EK, ER and NB are employees of the Clalit Research Institute, which received funding from Novo Nordisk. KB and MZ are Novo Nordisk employees. IR received personal fees from Novo Nordisk. Funding Information: The authors acknowledge the medical writing assistance of Caroline Freeman and Nicolas Bertheleme of Oxford PharmaGenesis Ltd, Oxford, UK. The medical writing agency was funded by Novo Nordisk International Operations. Novo Nordisk International Operations funded the study and participated in the conception of the design. ",

year = "2021",

month = aug,

doi = "10.1111/dom.14393",

language = "אנגלית",

volume = "23",

pages = "1995--2000",

journal = "Diabetes, Obesity and Metabolism",

issn = "1462-8902",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19

T2 - A retrospective, cohort study

AU - Hayek, Samah

AU - Ben-Shlomo, Yatir

AU - Balicer, Ran

AU - Byrne, Katherine

AU - Katz, Mark

AU - Kepten, Eldad

AU - Raz, Itamar

AU - Roitman, Eytan

AU - Zychma, Marcin

AU - Barda, Noam

N1 - Funding Information: SH, YB‐S, RB, MK, EK, ER and NB are employees of the Clalit Research Institute, which received funding from Novo Nordisk. KB and MZ are Novo Nordisk employees. IR received personal fees from Novo Nordisk. Funding Information: The authors acknowledge the medical writing assistance of Caroline Freeman and Nicolas Bertheleme of Oxford PharmaGenesis Ltd, Oxford, UK. The medical writing agency was funded by Novo Nordisk International Operations. Novo Nordisk International Operations funded the study and participated in the conception of the design.

PY - 2021/8

Y1 - 2021/8

UR - https://www.scopus.com/pages/publications/85104333149

U2 - 10.1111/dom.14393

DO - 10.1111/dom.14393

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 33822446

AN - SCOPUS:85104333149

SN - 1462-8902

VL - 23

SP - 1995

EP - 2000

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

IS - 8

ER -

Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study

Funding

UN SDGs

Access to Document

Other files and links

Cite this